Irinotecan
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Embryonal Tumor With Multilayered Rosettes, C19MC-Altered cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AZD1775 National Cancer Institute (NCI) | Phase 1/2 | CCC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
o6-benzylguanine National Cancer Institute (NCI) | Phase 1 | CC |
View all 11 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →